Acute myelogenous leukemia following treatment with cyclosporin A in a nephrotic patient

Internal Medicine

Volumn 41, Issue 9, 2002, Pages 722-724

  Ikeda, Yuji ^a   Sakemi, Takanobu ^a   Matsuzaki, Miwako ^a   Sano, Masayuki ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

AML; Diphenylhydantoin; Malignancy; Neoplasm; Nephrotic syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; DAUNORUBICIN; ENOCITABINE; PHENYTOIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CONVULSION; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; LEUKEMIA CELL; MALE; MYELOBLAST; NEPHROTIC SYNDROME; TREATMENT OUTCOME;

EID: 0036744425     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.722     Document Type: Article

References (15)

1. Zwanenburg TS, Suter W, Matter BE. Absence of genotoxic potential for cyclosporine in experimental systems. Transplant Proc 20: 931-933, 1988.
2. Ryffel B. Ezperimental toxicological studies with cyclosporin A. in: White DJG, E. Cyclosporin A: Proceedings of an international conference on cyclosporiD A, Cambridge (UK), September 1981. Elsevier, Amsterdam, 1982: 45-75.
3. Penn I. Cancers after cyclosporine therapy. Transplant Proc 20: 276-279, 1988.
4. Butler J, Korb S, Light J. Acute myelogenous leukemia in a renal allograft recipient receiving cyclosporine therapy. Transplantation 49: 813-815, 1990.
5. Casoli P, Tumiati B. Acute myelogeneous leukemia in a rheumatoid arthritis patient under cyclosporine A therapy. Clin Rheumatol 13: 646-647, 1994 (letter).
6. Ryffel B, Mihatsch MJ, Fisher GL. Immunosuppression and cancer: the ciclosporin case. Drug Chem Toxicol 15: 95-115, 1992.
7. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530-534, 1999 (see comments).
8. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137: 14-20, 2001.
9. Ohara A, Kojima S, Hamajima. N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 90: 1009-1013, 1997.
10. Eagen JW, Lewis EL Glomerulopathies of neoplasia. Kidney Int 11: 297-303, 1977.
11. Li FP, Willard DR, Goodman R, Vawter G. Malignant lymphoma after diphenylhydantoin (dilantin) therapy. Cancer 36: 1359-1362, 1975.
12. Sorrell TC, Forbes U, Burness FR, Rischbieth RH. Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 2: 1233-1235, 1971.
13. Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy-is there an association? Scand J Rheumatol 30:185-188, 2001.
14. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Does cyclosporin A cause cancer? Nat Med 5: 714, 1999 (letter).
15. Paul C, Hornig F. Risk of malignancy associated with cyclosporin use in psoriasis. Dermatology 198: 320-321, 1999 (letter).